Richard T. Schumacher, Founder, President, and CEO of Pressure BioSciences, Inc. Featured in PharmaWeek and PharmaDD

Business Wire, July 31, 2006

WEST BRIDGEWATER, Mass. -- Pressure BioSciences, Inc. (NASDAQ: PBIO) today announced that Richard T. Schumacher, its Founder, President, and CEO, was recently interviewed by Ms. Laurie Sullivan, Senior Editor of PharmaWeek, a weekly e-newsletter that is sent to over 33,000 subscribers. The interview was featured in the CEO Spotlight section of the newsletter; the interview was also included in PharmaDD, a drug discovery and development magazine.

In the interview, Mr. Schumacher discussed recent progress in the development of the Company's Pressure Cycling Technology (PCT) Sample Preparation System (PCT SPS), the various applications of PCT both within and outside of sample preparation, an overview of the Company's plan to achieve scientific acceptance and commercial success for its PCT product line, and some of the challenges and goals that lay ahead.

The interview has been posted to the www.pharmaweek.com and the www.pharmadd.com sites.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 4 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's use and availability of cash; the Company's plan to attend and present at future investor conferences; the potential market for and possible applications of the PCT SPS; the advantages of the PCT SPS over other currently available techniques; and the extent of possible acceptance of the PCT SPS by life sciences laboratories. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: uncertainties inherent in the development of the PCT SPS, including technical risks, cost overruns, and manufacturing and other delays; the risk that the market will not recognize the advantages of the PCT SPS over other currently available extraction methods; the risk that the PCT SPS will not achieve commercial acceptance for any of its potential applications; the risk that the Company will not have sufficient cash resources to achieve its objectives; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-QSB for the quarter ended March 31, 2006, in the Company's Annual Report on Form 10-KSB as amended, and in other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com